Matinas BioPharma reports complete clinical response in 3 fusarium patients with oral MAT2203

Matinas BioPharma Holdings, Inc.

Three patients with azole-resistant invasive fusarium infection achieved complete clinical response after oral MAT2203 treatment.
Two of these patients had not yet achieved complete resolution at the time of the prior 19-patient update.
Patients could not tolerate IV amphotericin B due to nephrotoxicity; oral MAT2203 resolved infections over 2 weeks to 6 months.
Results bolster confidence for upcoming Phase 3 ORALTO trial in invasive aspergillosis with limited treatment options.
MAT2203 is not yet licensed or approved anywhere globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.